GlassScriptPhysician profile
Shawn W Thomas
NPI 1043416506
$4,912.16
in general payments reported to CMS, 2019-2025
31 companies · $2,719 in 2025
The $2,719 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $354 · 2020: $106 · 2022: $164 · 2023: $710 · 2024: $859 · 2025: $2,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,416 · Food and Beverage: $1,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,416.26 |
| Food and Beverage | $1,872.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,809.37 | 2020-2025 | Speedicath |
| Medtronic, INC. | $1,135.88 | 2022-2025 | Altaviva, Interstim |
| Teleflex LLC | $613.26 | 2023-2025 | Urolift |
| Neotract INC. | $149.73 | 2019-2020 | |
| Boston Scientific Corporation | $140.93 | 2022 | |
| Endo USA, INC. | $80.76 | 2025 | Xiaflex |
| Emd Serono, INC. | $78.85 | 2019 | |
| Cook Medical LLC | $77.96 | 2019-2020 | |
| Becton, Dickinson and Company | $74.28 | 2023 | Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Profound Medical Corp. | $73.17 | 2025 | Tulsa-Pro |
| Myriad Genetic Laboratories, INC. | $66.33 | 2024 | Prolaris |
| Procept Biorobotics Corporation | $64.42 | 2025 | |
| Olympus America INC. | $54.35 | 2024-2025 | Itind System |
| Astellas Pharma US INC | $52.61 | 2019-2025 | Xtandi |
| Urogen Pharma, INC. | $50.94 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $44.47 | 2025 | Orgovyx, Gemtesa |
| Ambu INC. | $41.04 | 2024 | |
| Abbvie INC. | $38.29 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.68 | 2024 | |
| Tolmar, INC. | $29.15 | 2025 | Jatenzo, Eligard |
| Caris Mpi, INC. | $26.43 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $25.90 | 2025 | |
| Lsi Solutions INC | $25.34 | 2024 | Jnw Urtrac |
| Janssen Biotech, INC. | $22.38 | 2024 | Erleada |
| Karl Storz Endoscopy-America | $22.37 | 2019 | |
| 180 Medical, INC. | $19.60 | 2019 | |
| Photocure INC | $16.01 | 2019 | |
| Calyxo, INC. | $15.52 | 2025 | Cvac Aspiration System |
| Sandoz INC. | $13.86 | 2020 | |
| C. R. Bard, INC. & Subsidiaries | $10.82 | 2019 | |
| Civco Medical Instruments | $7.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.